There’s no denying that GLP-1 medications like Ozempic and Wegovy are having a moment. You’ve probably seen the headlines, ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Studies show that high-protein diets can help GLP-1 (glucagon-like peptide 1) medication users be more successful in their ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

That these treatments are helping people curb their eating should be no surprise: that is exactly what they are meant to do, by mimicking the satiety hormone GLP-1 (see “How they work”, below).

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

They work by mimicking the action of a hormone called glucagon-like peptide 1 (hence GLP-1), stimulating the body to produce more insulin and decreasing blood sugar spikes by slowing digestion.